DALLAS and NEW YORK, July 30,
2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB:
ACCP), a developer of new products for oncology supportive care,
announced that its novel product for oral mucositis,
MuGard®, has been featured in an article on
OncLive.com titled, "Study Finds Mouth Rinse Alleviates Oral
Mucositis Symptoms in Head and Neck Cancers." Dr.
Steve Sonis, a leading expert in
oral mucositis, provides insight on the growing demand seen in the
oncology community for evidence-based strategies for the
debilitating anticancer regimen side effect.
The article can be read by clicking on the following link:
http://www.onclive.com/publications/Oncology-live/2014/July-2014/Study-Finds-Mouth-Rinse-Alleviates-Oral-Mucositis-Symptoms-in-Head-and-Neck-Cancers#sthash.f3xlnzkt.dpuf
Oral Mucositis: Oral mucositis ("OM") is a debilitating
side effect of some radiation and chemotherapy cancer treatments,
characterized by sores and ulcers in the mouth and throat that make
swallowing difficult or impossible. It is estimated that 97% of
patients receiving radiation for head and neck cancer, 70% of
patients receiving stem cell transplantation and up to 40% of
patients receiving conventional chemotherapy develop oral
mucositis. There are an estimated 400,000 patients diagnosed with
OM in the US annually, but OM is often under-diagnosed and the
population at risk is significantly higher.
About MuGard: MuGard® Mucoadhesive Oral Wound Rinse
is indicated for the management of oral mucositis/stomatitis (that
may be caused by radiotherapy and/or chemotherapy) and all types of
oral wounds (mouth sores and injuries), including aphthous
ulcers/canker sores and traumatic ulcers, such as those caused by
oral surgery or ill-fitting dentures or braces. MuGard is available
by prescription only and is contraindicated in patients with known
hypersensitivity to any of the ingredients in the formulation.
MuGard received 510(k) clearance from the U.S. Food and Drug
Administration and is marketed by AMAG Pharmaceuticals, Inc. in the
United States. MuGard is also licensed in China with RHEI/Jian An, and in Korea with Hamni
Pharmaceuticals.
About Access: Access Pharmaceuticals, Inc. is an emerging
biopharmaceutical company that develops and commercializes
proprietary products for the treatment and supportive care of
cancer patients. Access developed MuGard and is developing multiple
follow-on products. Access also has other advanced drug delivery
technologies including CobaCyte™-mediated targeted delivery and
CobOral-oral drug delivery, its proprietary nanopolymer delivery
technology based on the natural vitamin B12 uptake mechanism. For
additional information on Access Pharmaceuticals, please visit our
website at www.accesspharma.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties.
These statements include those relating to: our cash burn rate,
clinical trial plans and timelines and clinical results for MuGard
and Cobalamin, our ability to achieve clinical and commercial
success and our ability to successfully develop marketed products.
These statements are subject to numerous risks, including but not
limited to Access' need to obtain additional financing in order to
continue the clinical trial and operations and to the risks
detailed in Access' Annual Reports on Form 10-K and other reports
filed by Access with the Securities and Exchange
Commission.
Company and Media Contact:
Christine Berni
VP Corporate Development
Access Pharmaceuticals, Inc.
(212) 786-6208
SOURCE Access Pharmaceuticals, Inc.